| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary targets of (3R)-7,4'-Dihydrohomoisoflavanone are bacterial pathogens, particularly Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). The compound exhibits potent antibacterial properties against both susceptible and resistant strains of S. aureus. It also demonstrates cytotoxicity with IC₅₀ values of 15.6 μg/mL and 30.2 μg/mL against certain cell lines.
|
|---|---|
| ln Vitro |
(3R)-7,4'-Dihydrohomoisoflavanone demonstrates cytotoxicity with IC50 values of 15.6 μg/mL, 30.2 μg/mL, and 20.5 μg/mL against the K-562, SMMC-7721, and SGC-7901 cell lines, respectively[1].
In vitro, (3R)-7,4'-Dihydrohomoisoflavanone demonstrates potent antibacterial activity against S. aureus and MRSA. The compound shows cytotoxicity with IC₅₀ values of 15.6 μg/mL and 30.2 μg/mL. As a natural homoisoflavanone, it has been characterized for its antibacterial properties. The antibacterial activity is concentration-dependent and has been demonstrated in standard microbiological assays. |
| ln Vivo |
In vivo activity of (3R)-7,4'-Dihydrohomoisoflavanone has not been extensively characterized. As a natural product with antibacterial effects, it has potential for treating bacterial infections. However, detailed in vivo pharmacokinetic and pharmacodynamic studies are limited. The compound is primarily studied for its antibacterial properties in vitro.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (3R)-7,4'-Dihydrohomoisoflavanone typically involve antibacterial susceptibility testing. Bacterial strains (e.g., S. aureus, MRSA) are cultured in appropriate media and treated with serial dilutions of the compound. The minimum inhibitory concentration (MIC) is determined after 16-24 hours of incubation at 37°C using the broth microdilution method. Cell viability is assessed by measuring optical density at 600 nm or by colony counting on agar plates. The compound demonstrates concentration-dependent antibacterial activity.
|
| Cell Assay |
In vitro cellular assays for (3R)-7,4'-Dihydrohomoisoflavanone involve testing its antibacterial activity against S. aureus and MRSA. Bacterial cultures are grown in appropriate media and treated with serial dilutions of the compound (ranging from 0.1 to 1000 µg/mL). After 16-24 hours of incubation at 37°C, the optical density at 600 nm is measured to determine bacterial growth inhibition. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) are calculated from the dose-response curves. The compound shows concentration-dependent antibacterial activity.
|
| Animal Protocol |
In vivo animal studies for (3R)-7,4'-Dihydrohomoisoflavanone are limited, as the compound is primarily studied in vitro. For antibacterial efficacy testing, animal models of bacterial infection (e.g., murine models of S. aureus infection) could be used. Animals would be treated with the compound via oral or intraperitoneal administration at various doses, and bacterial burden in target organs would be assessed. However, detailed in vivo protocols are not well established for this compound.
|
| ADME/Pharmacokinetics |
(3R)-7,4'-Dihydrohomoisoflavanone has a molecular formula of C₁₆H₁₄O₄ and a molecular weight of 270.28. The compound appears as a solid with a purity of ≥98%. It is a natural product with antibacterial properties against S. aureus and MRSA. The compound is intended for research use only and has not been approved for clinical use.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (3R)-7,4'-Dihydrohomoisoflavanone has not been extensively characterized. As a natural product, it is generally considered to have moderate toxicity. Standard toxicity studies would include assessment of acute oral toxicity, dermal irritation, and repeated-dose toxicity in animal models. The compound is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
Reports have indicated that agave contains 7,4'-dihydroxyisoflavones, and relevant data is available for reference.
(3R)-7,4'-Dihydrohomoisoflavanone (CAS 1178893-64-5) is a naturally occurring homoisoflavanone with antibacterial effect against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). It has a molecular formula of C₁₆H₁₄O₄ and a molecular weight of 270.28. The compound demonstrates cytotoxicity with IC₅₀ values of 15.6 μg/mL and 30.2 μg/mL. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C16H14O4
|
|---|---|
| Molecular Weight |
270.28
|
| Exact Mass |
270.089
|
| CAS # |
1178893-64-5
|
| PubChem CID |
3759709
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
524.5±50.0 °C at 760 mmHg
|
| Flash Point |
201.1±23.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.656
|
| LogP |
3.21
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2C=C(C=CC=2C(C(C1)CC1C=CC(=CC=1)O)=O)O
|
| InChi Key |
KKCLNMWDNUQXPP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14O4/c17-12-3-1-10(2-4-12)7-11-9-20-15-8-13(18)5-6-14(15)16(11)19/h1-6,8,11,17-18H,7,9H2
|
| Chemical Name |
7-hydroxy-3-[(4-hydroxyphenyl)methyl]-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
